IceCure Completes 5-Year Kidney Cancer Cryoablation Study, Final Data Due Mid-2026

Event summary

  • IceCure Medical completed 5-year follow-up in ICESECRET trial for ProSense® cryoablation in kidney cancer.
  • Interim 3-year data showed 88.7% recurrence-free rate in 111 patients.
  • Final analysis expected in Q2 2026, with regulatory approvals already in U.S. and Europe.
  • Study focused on small renal masses (SRMs) ≤5 cm, addressing unmet needs in elderly/comorbid patients.

The big picture

IceCure's completion of the ICESECRET trial underscores the growing demand for minimally invasive, nephron-sparing treatments in kidney cancer, particularly as SRMs become more prevalent through widespread imaging. With 400,000 new kidney cancer cases globally, the study's final data could position ProSense® as a key player in addressing unmet needs, especially for patients unsuitable for surgery. The strategic focus on liquid nitrogen-based cryoablation aligns with broader trends toward outpatient, office-based procedures in oncology.

What we're watching

Regulatory Expansion
Whether IceCure can leverage existing approvals to accelerate adoption in Israel and other markets.
Clinical Adoption
The pace at which ProSense® gains traction among elderly/comorbid patients ineligible for surgery.
Competitive Positioning
How ProSense® differentiates against surgical and other minimally invasive alternatives in kidney cancer.

Related topics

Oncology